Stock 6660 AIM VACCINE CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

AIM Vaccine Co., Ltd. Stock

Equities

6660

CNE100005KF2

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:09:13 2024-04-23 am EDT 		5-day change 1st Jan Change
8.39 HKD +0.72% Intraday chart for AIM Vaccine Co., Ltd. -1.29% +6.88%
Mar. 28 Aim Vaccine Submits Pre-Applications for Clinical Trials for Two Vaccines; Shares Up 3% MT
Mar. 28 Aim Vaccine's Loss Quadruples in 2023 as Revenue Slips 6%; Shares Up 3% MT

Financials

Sales 2023 1.19B 164M 1.28B Sales 2024 * 3.41B 470M 3.68B Capitalization 9.33B 1.29B 10.08B
Net income 2023 * - Net income 2024 * - EV / Sales 2023 8.17 x
Net Debt 2023 1.06B 146M 1.15B Net Debt 2024 * 904M 125M 978M EV / Sales 2024 * 3 x
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees 1,624
Yield 2023 *
0.41%
Yield 2024 *
1.65%
Free-Float 22.09%
More Fundamentals * Assessed data

Chart AIM Vaccine Co., Ltd.

Dynamic Chart

Latest news about AIM Vaccine Co., Ltd.

Aim Vaccine Submits Pre-Applications for Clinical Trials for Two Vaccines; Shares Up 3% MT
Aim Vaccine's Loss Quadruples in 2023 as Revenue Slips 6%; Shares Up 3% MT
AIM Vaccine Co., Ltd. Submits the Pre- Application for Clinical Trials for Haemophilus Influenzae Type B Conjugate Vaccine CI
AIM Vaccine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
AIM Vaccine Co., Ltd. Submits the Pre- Application for Clinical Trials for quadrivalent influenza virus vaccine (MDCK Cells) CI
Aim Vaccine Submits Clinical Trial's Pre-Application for Rabies Vaccine MT
AIM Vaccine Co., Ltd. Submits Pre-Application for Clinical Trials for Novel-Process Highly-Effective Human Diploid Rabies Vaccine CI
AIM Vaccine Files Pre-Application for Marketing Registration of its Pneumonia Vaccine MT
AIM Vaccine Boosts Development of Iterative Pneumonia Series Vaccines MT
AIM Vaccine Expediting Development of Iterative Rabies Series Vaccines; Shares Drop 4% MT
AIM Vaccine Advances Trial of Meningococcal Vaccine in China; Shares Fall 4% MT
AIM Vaccine Expects Wider Loss in 2023; Shares Slide 4% MT
AIM Vaccine Submits Pre-Application for Clinical Trials for Absorbed Tetanus Vaccine; Shares Fall 3% MT
Aim Vaccine Co., Ltd. Initiation of Phase II Clinical Trial of Tetravalent Meningococcal Conjugate Vaccine CI
AIM Vaccine Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023 CI
More news

Analyst Recommendations on AIM Vaccine Co., Ltd.

AIM Vaccine's COVID-19 Vaccine Protection Rates Reach As High As 80% in China Clinical Study MT
More recommendations

Quotes and Performance

1 day+0.72%
1 week-0.12%
Current month+3.20%
1 month+4.09%
3 months+16.69%
6 months-13.95%
Current year+6.88%
More quotes

Highs and lows

1 week
8.16
Extreme 8.16
8.69
1 month
7.79
Extreme 7.79
9.00
Current year
6.06
Extreme 6.06
9.05
1 year
6.06
Extreme 6.06
55.40
3 years
6.06
Extreme 6.06
100.00
5 years
6.06
Extreme 6.06
100.00
10 years
6.06
Extreme 6.06
100.00
More quotes

Managers and Directors - AIM Vaccine Co., Ltd.

Managers TitleAgeSince
Yan Zhou CEO
 Chief Executive Officer 58 15-04-30
Wen Guan PSD
 President 57 16-11-30
Li Xin Niu DFI
 Director of Finance/CFO 52 15-09-30
Members of the board TitleAgeSince
Ker Wei Pei BRD
 Director/Board Member 67 20-09-18
Xin Zhou BRD
 Director/Board Member 55 13-04-30
Yan Zhou CEO
 Chief Executive Officer 58 15-04-30
More insiders

Quotes

Date Price Change Volume
24-04-23 8.39 +0.72% 51 400
24-04-22 8.33 +0.97% 196,200
24-04-19 8.25 -0.84% 170,600
24-04-18 8.32 +0.60% 154,000
24-04-17 8.27 -1.55% 70,600

Delayed Quote Hong Kong S.E., April 23, 2024 at 04:09 am EDT

More quotes

Company Profile

AIM Vaccine Co Ltd is a China-based company principally engaged in the research and development, manufacturing and sales of vaccine. The Company's products mainly include recombinant hepatitis B vaccine, human rabies vaccine, inactivated hepatitis A vaccine, mumps vaccine, inactivated hemorrhagic fever with renal syndrome vaccine and MPSV4. The Company's products are mainly used for the treatment of hepatitis B, hepatitis A, mumps, hemorrhagic fever with renal syndrome, rabies and meningococcal diseases. The Company's vaccine candidates include messenger RNA (mRNA) corona virus disease 2019 (COVID-19) vaccine, inactivated COVID-19 vaccine, broad-spectrum COVID-19 vaccine, PCV13, PPSV23 and MCV4. The Company principally conducts its businesses in the domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-28 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for AIM Vaccine Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
7.7 CNY
Average target price
48.74 CNY
Spread / Average Target
+533.01%
Consensus

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
AIM VACCINE CO., LTD. Stock AIM Vaccine Co., Ltd.
+6.88% 1.29B
CSL LIMITED Stock CSL Limited
-2.68% 85.68B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+5.53% 41.4B
BIOGEN INC. Stock Biogen Inc.
-24.99% 28.22B
UCB Stock UCB
+55.64% 24.64B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-7.19% 16.98B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-34.20% 13.29B
INCYTE CORPORATION Stock Incyte Corporation
-17.31% 11.66B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-11.43% 11.65B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
-0.67% 8.18B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 6660 Stock